Introduction:
Leading pharma company has launched an immuno-oncology drug in India for recurrent or metastatic nasopharyngeal carcinoma. Approved globally, it reduces disease progression risk by 48%, representing a major breakthrough in cancer care and advanced treatment options.
Also Read: Infra stock jumps 5% after it receives order worth ₹1,704 Cr from Power Grid
Share price movement of Dr. Reddy’s Laboratories:
On November 28, 2024, Dr. Reddy’s Laboratories Ltd. opened at ₹1,200.65, slightly up from the previous close of ₹1,200.50. The stock hit a high of ₹1,210.40 and a low of ₹1,188.65. By 1:58 PM, it traded at ₹1,194.80, down 0.47%, with a full market capitalization of ₹99,687.62 crore.
Dr. Reddy’s Launches Toripalimab:
Dr. Reddy’s Laboratories has launched Toripalimab in India, an immuno-oncology drug for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Approved by global regulators like USFDA and EMA, it reduces disease progression risk by 48%, offering significant hope.
Marketed under the brand name Zytorvi®, Toripalimab makes India the third country after the U.S. and China to access this PD-1 inhibitor. The launch follows Dr. Reddy’s licensing deal with Shanghai Junshi Biosciences for commercialization in 21 countries, including India and Brazil.
This innovative drug underscores Dr. Reddy’s commitment to advancing cancer treatment. By leveraging global partnerships and technology, the company is poised to transform oncology care in India and expand its reach in international markets.
Recent news on Dr. Reddy’s Laboratories:
As of November 22, 2024, Dr. Reddy’s Laboratories, along with five other major pharmaceutical firms, has signed agreements to set up new facilities in Telangana’s Pharma City. The collective investment exceeds ₹5,260 crore, expected to create 12,490 jobs in the sector.
Stock performance of Dr. Reddy’s Laboratories for Period of 1 week, 6 months and 1 year:
Dr. Reddy’s Laboratories Ltd has seen a modest increase of 0.38% over the past week. The stock has delivered a 3.59% return over the last six months, with a solid 4.97% growth year-on-year, reflecting steady performance and growth potential in the long term.
Also Read: Navratna stock jumps 5% after it signs MoU with NBCC for 10 acres of land parcel development
Shareholding pattern of Dr. Reddy’s Laboratories:
| All values in % | Sep 2024 | Jun 2024 | Mar 2024 |
| Promoter | 26.60% | 26.70% | 26.70% |
| FII | 27.50% | 27.70% | 29.10% |
| DII | 35.70% | 35.30% | 33.70% |
| Public | 10.00% | 10.20% | 10.40% |
| Others | 0.20% | 0.20% | 0.20% |
About Dr. Reddy’s Laboratories:
Dr. Reddy’s Laboratories (NSE: DRREDDY) is a global pharmaceutical company, specializing in generic medicines, active pharmaceutical ingredients (APIs), and biosimilars. The company focuses on advancing healthcare through innovative solutions and global partnerships.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
